Taken together, these results suggest that amurensin H exerted its anti-COPD inflammation effect partly through inhibition of expression of p-Syk and activation of NF-κB to modulate Syk/NF-κB pathway. This evidence concerns the gene NFKB1 and chronic obstructive pulmonary disease.